RM-718 trial data puts Rhythm Pharmaceuticals (RYTM) pipeline in focus

Rhythm Pharmaceuticals (RYTM) has drawn fresh investor attention after releasing preliminary Phase 2 data for RM-718 in acquired hypothalamic obesity, showing double digit mean BMI reductions and a generally well tolerated safety profile.

The RM-718 update has arrived alongside a sharp pickup in Rhythm Pharmaceuticals' share price momentum, with a 7-day share price return of 16.5% and a 90-day share price return of 22.79% helping lift year-to-date gains to 10.11%. The 1-year total shareholder return of 25.71% sits on top of a very large 5-year total shareholder return that reflects how strongly the story has evolved over time.

If the RM-718 data has you looking at obesity and metabolic treatments more closely, it could be a good moment to see what else is moving in healthcare AI and related drug discovery using the 43 healthcare AI stocks

After a move that already reflects fresh RM-718 enthusiasm, the key tension now is clear. Is Rhythm Pharmaceuticals' recent rerating just the first leg of a longer rerate, or has most of the easy upside already been priced in?

Most Popular Narrative: 17.1% Undervalued

The most followed narrative on Rhythm Pharmaceuticals currently points to a fair value of $139.47 per share versus the last close of $115.63, which implies meaningful upside if those assumptions play out.

Upcoming potential regulatory approvals and launches for setmelanotide (IMCIVREE) in new indications like acquired hypothalamic obesity and Prader-Willi syndrome, alongside expansion into younger age groups, are set to materially grow Rhythm's commercial opportunity and topline over the next several years.

Want to understand why this narrative supports a higher fair value for Rhythm Pharmaceuticals? The story leans heavily on rapid revenue expansion, a sharp earnings swing, and a premium profit multiple tied to those future numbers. The key is how confidently those projections hold up under your own assumptions.

Result: Fair Value of $139.47 (UNDERVALUED)

However, investors still need to weigh Rhythm Pharmaceuticals' ongoing losses and heavy reliance on setmelanotide, as any clinical or regulatory setback could quickly challenge this positive narrative.

Another View on Rhythm Pharmaceuticals Valuation

The headline narrative suggests Rhythm Pharmaceuticals is about 17.1% undervalued based on future earnings assumptions and a forward P/E of 48.8x. A different lens using the current P/S of 33.2x paints a less comfortable picture when set against a fair ratio of 19.5x, the US Biotechs average of 11.6x, and a peer average of 9.1x. That gap points to meaningful valuation risk if sentiment on growth cools even slightly, so how much of a premium are you really willing to underwrite here?

Next Steps

With sentiment around Rhythm Pharmaceuticals leaning positive, it makes sense to move quickly and test the narrative against your own expectations and risk tolerance. You can start by reviewing the 3 key rewards

Looking for more investment ideas beyond Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals may be front of mind today, but your next opportunity could sit in a very different corner of the market. Use the Simply Wall St Screener to keep your watchlist fresh and avoid missing what others overlook.

• Target potential standouts that trade below their estimated worth by scanning the market for 51 high quality undervalued stocks.
• Strengthen your defense by focusing on companies that pair financial resilience with consistent fundamentals through the solid balance sheet and fundamentals stocks screener (49 results).
• Hunt for overlooked prospects that combine quality metrics with lower market attention using the screener containing 19 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.